Efficacy of twice-daily amoxycillin/clavulanate in lower respiratory tract infections.
|
| Abstract |
In this double-blind, double-dummy study, 324 patients with clinical evidence of community-acquired pneumonia (CAP) or an acute exacerbation of chronic bronchitis were randomly assigned to receive 10 days' treatment with either amoxycillin/clavulanate 875/125 mg twice daily or amoxycillin/clavulanate 500/125 mg three times daily. At the end of therapy, clinical success rates were 92.4% for the twice daily regimen and 94.2% for the three times daily regimen. There was no statistically significant difference between treatments (p = 0.647) and the 95% confidence interval around the treatment difference indicated that the two treatments were equivalent. Treatment equivalence was also confirmed at follow-up, four weeks after the end of treatment. Both regimens were well tolerated. In conclusion, amoxycillin/clavulanate 875/125 mg twice daily is as effective as amoxycillin/clavulanate 500/125 mg three times daily for the treatment of community-acquired lower respiratory tract infections and could improve patient compliance.
|
|---|---|
| Authors | A A Balgos, G Rodriguez-Gomez, R Nasnas, A A Mahasur, B P Margono, J C Tinoco-Favila, R H Sansores-Martinez, M Hassan, O Beppo, A Wongsa, A Cukier, F Vargas |
| Journal | International journal of clinical practice (Int J Clin Pract) 1999 Jul-Aug Vol. 53 Issue 5 Pg. 325-30 ISSN: 1368-5031 [Print] India |
| PMID | 10695094 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!